Gene Therapy On Neurological Diseases Market Trends And Growth Drivers Point To Strong Future Potential
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Gene Therapy On Neurological Diseases Market Growth Potential: How Will Market Size Change Through 2030?
The market for gene therapy targeting neurological disorders has seen swift expansion in recent years. Valued at $3.55 billion in 2025, it is projected to reach $4.01 billion by 2026, reflecting a compound annual growth rate (CAGR) of 13.0%. This historical growth has been driven by several factors, including the scarcity of available gene therapy options for neurological conditions, the rising incidence of Alzheimer’s and Parkinson’s diseases, a continued dependence on conventional treatment modalities, heightened awareness of genetic strategies, and the early-stage clinical testing of viral vectors.
The market for gene therapy targeting neurological diseases is projected to experience substantial expansion in the coming years. By 2030, its value is forecasted to reach $6.48 billion, reflecting a compound annual growth rate (CAGR) of 12.7%. This anticipated growth is driven by several factors, including the advancement of therapies based on adeno-associated viruses and lentiviruses, the broader development of non-viral delivery systems, an increase in regulatory approvals for neurological gene therapies, heightened investment in research and development focused on targeted genetic interventions, and the incorporation of digital monitoring tools along with AI-driven patient management approaches. Key trends shaping the forecast period involve growing financial commitments to both viral and non-viral gene therapy platforms, an expansion in the use of gene therapy for various neurological conditions, a heightened emphasis on personalized and precisely targeted genetic treatments, the proliferation of hospital and clinic-based gene therapy initiatives, and the creation of innovative delivery methods to advance neurological gene therapy.
Download A Free Sample Report For Comprehensive Market Insights:
Gene Therapy On Neurological Diseases Market Opportunity Drivers: What Is Creating New Revenue Potential?
The rising incidence of neurological disorders is anticipated to accelerate the expansion of the gene therapy market for neurological diseases in the foreseeable future. Neurological disorders encompass medical conditions that impact the brain, spinal cord, and nerves, resulting in various symptoms such as cognitive, motor, and sensory deficits. This uptick in neurological disorder cases is attributed to an aging population, where aging progressively diminishes neuronal function, reduces brain plasticity, and heightens oxidative stress, thereby facilitating the onset and advancement of these conditions. Gene therapy for neurological diseases supports the management of such disorders by addressing fundamental genetic causes, providing potentially lasting or permanent therapeutic options. It enhances patient outcomes by correcting or adjusting gene activity, alleviating symptoms, and decreasing the need for repeated treatments, thus improving overall life quality. For example, in July 2024, the National Health Service, a government organization in the UK, reported 487,432 patients diagnosed with dementia—a progressive brain disorder affecting memory, thinking, and daily activities—by June 30, 2024, marking an increase of 3,155 cases from May 31, 2024. Consequently, the growing frequency of neurological disorders is fueling the progression of the gene therapy market for neurological diseases.
Gene Therapy On Neurological Diseases Market Segment Outlook: Which Categories Are Expanding The Fastest?
The gene therapy on neurological diseases market covered in this report is segmented –
1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy
2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis
3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus
2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)
Gene Therapy On Neurological Diseases Market Innovation Trends Driving Future Development
Major players in the gene therapy for neurological diseases market are concentrating on the development of sophisticated viral delivery platforms—like the adeno-associated virus serotype 2 (AAV2) vector—aimed at refining targeted gene transfer, boosting therapeutic effectiveness, lowering immune responses, and facilitating enduring treatments. Such a vector is described as a genetically engineered, non-harmful viral carrier employed in gene therapy to deliver therapeutic genes to specific cells, especially neurons, allowing sustained expression. As an example, in November 2024, PTC Therapeutics Inc., a biopharmaceutical firm based in the United States, obtained approval from the U.S. Food and Drug Administration (FDA) for a gene therapy targeting aromatic L-amino acid decarboxylase (AADC) deficiency. This treatment leverages an AAV2 vector to transport a functional DDC gene copy into the putamen, thereby enabling dopamine synthesis and enhancing motor capabilities. It involves a single, intraputaminal infusion intended to deliver lasting therapeutic advantages, markedly improving motor function and alleviating severe symptoms while eliminating the requirement for repeated treatments.
Gene Therapy On Neurological Diseases Market Key Companies And Competitive Benchmarking
Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG
Access The Complete Gene Therapy On Neurological Diseases Market Report:
Gene Therapy On Neurological Diseases Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
